Carcinogenic nitrogen compounds. Part LXVI. A new heterocyclic system : 5H-1,4-benzodithiino[2,3-b]indole
作者:N. P. Buu-Hoï、P. Jacquignon、L. Ledésert、A. Ricci、D. Balucani
DOI:10.1039/j39690002196
日期:——
The novel systems, 5H-1,4-benzodithiino[2,3-b]indole, and 13H-1,4-benzodithiino[2,3-b]pyrido[3′,2′-g]indole, have been prepared from 1,4-benzodithiin-2(3H)-one and the appropriate hydrazine.
新的系统5 H -1,4-苯并二噻吩并[2,3- b ]吲哚和13 H -1,4-苯并二噻吩并[ 2,3- b ]吡啶并[3',2'- g ]吲哚具有由1,4-苯并二硫辛-2(3H)-1和适当的肼制得。
Preventives and remedies for central nervous system diseases
申请人:——
公开号:US20030207863A1
公开(公告)日:2003-11-06
A prophylactic or therapeutic agent for central nervous system diseases based on amyloid &bgr;40 secretion inhibitory activity of a compound having urotensin II receptor antagonistic activity or a salt thereof.
Agents and crystals for improving excretory potency of urinary bladder
申请人:——
公开号:US20020177593A1
公开(公告)日:2002-11-28
Agents for improving potentcy of the urinary bladder which comprises an amine compound of non-carbamate-type having an acetylcholinesterase-inhibiting action. Particularly, crystals of a tricyclic, condensed, heterocyclic derivative are provided, which possess an excellent action to inhibit acetylcholine esterase and an action to improve the excretory potency of urinary bladder. As an example, crystals of of 8-[3-[1-[(3-fluorophenyl)-methyl]-4-piperidinyl]-1-oxopropyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one or a salt thereof and pharmaceutical compositions containing them are disclosed.
Agents for improving excretory potency of urinary bladder
申请人:——
公开号:US20040116457A1
公开(公告)日:2004-06-17
Agents for improving excretory potency of the urinary bladder which comprises an amine compound of non-carbamate-type having an acetylcholinesterase-inhibiting action.
改善排泄能力的尿道代理,包括一种非卡巴酯型胺类化合物,具有乙酰胆碱酯酶抑制作用。
Preventives/remedies for urinary disturbance
申请人:Ishihara Yuji
公开号:US20050197362A1
公开(公告)日:2005-09-08
Preventives/remedies for voiding disturbance containing a compound having both of an acetylcholinesterase inhibitory action and an α1 antagonistic action which exhibits an excellent effect of improving the urinary function of the bladder (i.e., effects of improving urine flow rate and voiding efficiency) without affecting the urinary pressure or the blood pressure.